Your browser is no longer supported. Please, upgrade your browser.
SYBX [NASD]
Synlogic, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own0.10% Shs Outstand36.30M Perf Week25.46%
Market Cap148.71M Forward P/E- EPS next Y-1.56 Insider Trans0.00% Shs Float28.26M Perf Month88.48%
Income-57.40M PEG- EPS next Q-0.41 Inst Own39.90% Short Float2.28% Perf Quarter101.48%
Sales1.80M P/S82.62 EPS this Y16.40% Inst Trans0.04% Short Ratio0.34 Perf Half Y86.76%
Book/sh3.32 P/B1.23 EPS next Y6.60% ROA-34.40% Target Price- Perf Year49.27%
Cash/sh2.81 P/C1.46 EPS next 5Y- ROE-41.60% 52W Range1.35 - 4.30 Perf YTD89.35%
Dividend- P/FCF- EPS past 5Y23.60% ROI-34.60% 52W High-4.88% Beta2.26
Dividend %- Quick Ratio16.40 Sales past 5Y- Gross Margin- 52W Low202.96% ATR0.30
Employees76 Current Ratio16.40 Sales Q/Q- Oper. Margin- RSI (14)81.52 Volatility11.04% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q6.20% Profit Margin- Rel Volume0.27 Prev Close4.27
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume1.90M Price4.09
Recom1.70 SMA2052.38% SMA5069.70% SMA20084.99% Volume520,636 Change-4.22%
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Jan-14-21 08:56AM  
05:28AM  
Jan-11-21 06:30AM  
Dec-14-20 11:41AM  
06:00AM  
Dec-09-20 06:30AM  
Dec-07-20 12:27PM  
Dec-02-20 10:47PM  
Nov-27-20 08:47AM  
Nov-18-20 06:30AM  
Nov-09-20 10:04AM  
Nov-05-20 08:42AM  
07:54AM  
06:30AM  
Nov-04-20 04:05PM  
Oct-27-20 06:30AM  
Oct-22-20 06:30AM  
Sep-14-20 07:00AM  
Sep-10-20 02:15PM  
Sep-08-20 11:46AM  
Aug-28-20 09:37AM  
Aug-24-20 03:30PM  
Aug-06-20 07:00AM  
Jul-31-20 02:49PM  
Jul-30-20 07:00AM  
Jul-28-20 07:30AM  
Jun-17-20 09:38PM  
Jun-12-20 11:19AM  
Jun-01-20 05:46AM  
May-27-20 08:00AM  
May-21-20 04:02PM  
08:01AM  
06:00AM  
May-08-20 07:44AM  
06:00AM  
May-04-20 04:02PM  
Apr-01-20 07:32AM  
Mar-30-20 06:00AM  
Mar-15-20 11:00AM  
Mar-12-20 04:19PM  
03:00PM  
Mar-11-20 04:02PM  
Mar-05-20 04:02PM  
Feb-19-20 02:04PM  
Feb-18-20 04:02PM  
Jan-24-20 08:01AM  
Jan-14-20 08:33AM  
Jan-09-20 06:00AM  
Jan-06-20 09:20AM  
Dec-20-19 03:29PM  
Dec-12-19 07:55AM  
Dec-11-19 06:00AM  
Dec-10-19 07:00AM  
Dec-05-19 02:37PM  
Nov-25-19 04:02PM  
04:02PM  
Nov-14-19 11:41AM  
Nov-12-19 04:02PM  
Nov-07-19 03:07PM  
Nov-05-19 04:02PM  
Sep-30-19 04:02PM  
Sep-26-19 07:00AM  
Sep-25-19 05:23PM  
Sep-12-19 12:56PM  
Sep-06-19 03:46PM  
Sep-05-19 08:12AM  
Sep-04-19 04:01PM  
06:00AM  
Aug-24-19 01:46PM  
Aug-21-19 06:03PM  
Aug-20-19 07:38AM  
07:33AM  
06:00AM  
Aug-08-19 05:00PM  
04:02PM  
06:38AM  
Aug-01-19 04:02PM  
Jul-25-19 09:54AM  
Jul-15-19 06:00AM  
Jul-01-19 01:10PM  
Jun-12-19 06:30AM  
May-23-19 04:15PM  
May-22-19 07:00AM  
May-16-19 09:14PM  
May-15-19 01:12PM  
May-09-19 04:02PM  
May-02-19 04:05PM  
Apr-30-19 07:00AM  
Apr-26-19 04:26PM  
11:43AM  
Apr-15-19 04:10PM  
Apr-09-19 07:00AM  
Apr-02-19 04:05PM  
Mar-18-19 11:41AM  
Mar-13-19 04:05PM  
Mar-12-19 07:00AM  
Mar-06-19 07:00AM  
Mar-05-19 04:05PM  
Feb-28-19 05:00PM  
Feb-20-19 04:02PM  
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.